Max Healthcare Institute growth ratios

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendFY26Mar 2026FY25Mar 2025FY24Mar 2024FY22 and earlierAlpha Plus
+19.1%+30.0%+18.5%
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
+21.3%+23.9%+20.3%
+20.6%+19.4%+23.7%
+34.1%+1.7%−4.2%
+34.0%+1.7%−4.3%
+13.3%+26.8%+18.8%
+14.6%+11.6%+13.5%
+11.9%+30.1%−7.2%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

MAXHEALTH₹851.15

Max Healthcare Institute Ltd.

· Pharma & Health
₹ CrorePeersAPOLLOHOSPFORTISMEDANTADRREDDYCIPLASUNPHARMADIVISLABTORNTPHARMMcap ₹82,828 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/09/2026
Revenue Growth—+18.5+30.0+19.1—
EBITDA Growth—+20.3+23.9+21.3—
EBIT Growth—+23.7+19.4+20.6—
Net Income Growth—-4.2+1.7+34.1—
EPS Growth—-4.3+1.7+34.0—
Total Assets Growth—+18.8+26.8+13.3—
Total Equity Growth—+13.5+11.6+14.6—
Cash from Operations Growth—-7.2+30.1+11.9—
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 146%.